FDA Head Says A COVID-19 Vaccine Could Get Emergency Approval Without Phase 3 Trial Results: FT

The United States Food and Drug Administration is willing to expedite the COVID-19 vaccine authorization process, including granting emergency use authorization to a candidate before it completes late-stage clinical trials, according to Chairman Stephen Hahn.

What Happened: Hanh told the Financial Times that the FDA will only take such a step after weighing the risks and benefits of any coronavirus vaccine, instead of using the procedure as a tool for a political agenda before the 2020 Presidential elections.

Hahn reportedly told FT that the federal agency is prepared to approve a vaccine before the completion of phase three clinical trials. The FDA commissioner also hinted at the possibility of issuing emergency authorization for use in restricted groups, rather than a blanket approval.

One of the significant points in consideration for the upcoming 2020 elections is the response to the pandemic outbreak by the current administration. However, the FDA clarified that its decision to sanction trials will not be driven by the re-election prospects of Donald Trump.

AstraZeneca Plc AZN is working on a vaccine with Oxford University, which could be fast-tracked by the administration in September before the Stage Three trials are successfully completed, according to another FT report. 

Pfizer Inc PFE, Johnson and Johnson JNJModerna Inc. MRNA, and Inovio Pharmaceuticals Inc INO are also performing clinical trials for their COVID-19 vaccine candidates.

Why It Matters: Vaccine manufacturers face a systematic and inevitable risk during testing and there is a lobby actively seeking protection against litigation in the European Union. Reports suggest that AstraZeneca has already managed to receive liability protection in certain countries.

The FDA earlier this month granted EUA for use of convalescent plasma to treat hospitalized COVID-19 patients.

Photo courtesy: U.S. Department of Defense

Posted In: CoronavirusCoronavirus VaccineCovid-19The Financial TimesU.S. Food and Drug AdministrationBiotechNewsHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.